RTSN Retension Pharmaceuticals, Inc. Common Stock
10.53USDMkt Cap: 82.99M $P/E: —Today
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, sm…
Industry Peers
Biotechnology$129.20BUSDP/E 29.7
$89.83BUSD
$76.86BUSDP/E 18.5
$51.88BUSDP/E 31.4
$49.79BUSDP/E 32.4
$42.17BUSDP/E 18.0
$40.67BUSD
$40.33BUSDP/E 63.4
$32.90BUSDP/E 30.3
$31.13BUSDP/E 39.2
$25.60BUSD
$24.36BUSD
$22.86BUSDP/E 14.4
$22.79BUSDP/E 29.2
$21.90BUSDP/E 30.2
$21.97BUSD
$15.08BUSDP/E 17.6
$14.83BUSDP/E 18.9
$14.18BUSDP/E 15.0
$14.03BUSD
Key Statistics
Company
Market Cap82.99M USD
Enterprise Value74.85M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-14.24M USD
Revenue/Share—
Last Price10.53 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B—
EPS (TTM)—
EPS (Forward)—
52W Range
9.66045% of range11.60
52W High11.60 USD
52W Low9.660 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE—
ROA—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-11.89M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-13.49M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio5.61
Quick Ratio4.69
Book Value/Sh—
Cash/Share2.69 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.7.88M
Float—
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta—
S&P 52W Chg18.51%
Avg Vol (30d)788.15K
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—